The National Institute on Aging's Cellular Biophysics Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biological pacemakers.
The National Cancer Institute seeks partners to license a composition for use in an aerosol or spray, that when administered, causes a painful stimulation and incapacitates a person for only a brief period.
The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).
Glioblastoma Multiforme (GBM) is the most common and devastating form of brain cancer. Despite existing conventional therapies, including an initial surgical resection followed by chemotherapy and radiation, GBM has a median survival of approximately 15 months and a two-year survival rate of 30%. The NICHD seeks parties interested in collaborative research to co-develop or license a cancer therapy device that uses induced electric fields.
Testing for biological activity of glucocorticoids and many other steroid endocrine-disrupting chemicals (EDCs) has not been previously performed. An automated, highly reproducible, and low cost assay detects biologically active steroidal EDCs and is suitable for wide application in testing water samples. The National Cancer Institute seeks partners for collaborative co-development research and/or licensing to move this technology into the public domain.
Electron paramagnetic resonance (EPR) is a technique for studying chemical species that have one or more unpaired electrons. The current invention describes Echo-based Single Point Imaging (ESPI), a novel EPR image formation strategy that allows in vivo imaging of physiological function. The National Cancer Institute's Radiation Biology Branch is seeking statements of capability or interest from parties interested in in-licensing an in vivo imaging using Electron paramagnetic resonance (EPR) to measure active oxygen species.
Researchers in the National Cancer Institute’s Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. NCI seeks partners to license this technology.
The technology is a tool used to hold transmission electron microscopy grids to grow adherent mammalian cells on and the 3D printing software to create the holder. The TEM cell grid holder solves the difficulty of lifting the TEM grid out of a plate without bending or damaging the grid. Researchers at the NCI seek licensing for the transmission electron microscopy grid holder.
Device is used to guide a stream of oxygen or carbon dioxide over a dish of cells during fluorescence microscopy. Invention includes the 3D printing software to create the device. The device makes it possible to easily provide a steady source of oxygen or carbon dioxide to cells while operating a fluorescent microscope to oxidize fluorophores for later visualization in electron microscopy. NCI seeks commercial partners to license this technology.
The National Cancer Institute seeks partners for licensing and/or co-development of a molecular technology that can detect and/or modify molecules. Each tether tip has a functional group, such as an antibody or oligonucleotide that recognizes a target molecule. In addition, one tip carries a donor fluorophore and the other carries an acceptor fluorophore. The fluorophores form a pair for Forster Resonance Energy Transfer (FRET). In the absence of the target molecule, the rod keeps the tether arms apart, while in the presence of the target molecule, both recognizers bind to the target.
The sequencer utilizes Forster Resonance Energy Transfer (FRET) to read a polynucleotide sequence while synthesizing a complementary strand. The National Cancer Institute seeks partners to license or co-develop the technology.
Chronic graft-versus-host disease (cGVHD) is a prevalent and highly lethal condition affecting stem cell transplant recipients. Unfortunately, biopsies are a painful, invasive and slow procedure that cause discomfort to patients and does not yield rapid results. The National Cancer Institute seeks licensees to commercialize this improved method for detection of diseases that are characterized by the presence of rapidly-dividing cells using deuterated water as a label for dynamic measurement of in vivo cellular kinetics.
This surgical clamp device is particularly useful for intraocular surgeries requiring incision in the sclera. The device provides ease of use for repeated opening and closure of an incision or wound for entry of instruments into the eye. It maintains precise alignment of the wound margins, reducing loss of intraocular fluid and pressure. The NEI seeks licensees or collaborative co-development of this invention so that it can be commercialized.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license or co-develop this technology toward commercialization.
Researchers at the National Eye Institute (NEI), have developed a cryopreservation and cell recovery system designed specifically for the efficient cryopreservation, transportation and subsequent thawing of monolayers and tissues on a substrate. This closed cryopreservation/defrost system allows for sterility in addition to increased viability, recovery and safety of tissues that can be used for in vitro culture or surgical transplantation.
Researchers at the National Institute on Drug Abuse (NIDA) have developed an apparatus that is used to image rodents (rats) while they are awake. The biological effects of agents on the rats can be imaged (via MRI for instance) in real time over a prolonged period of time.
Researchers at the National Cancer Institute (NCI) and Center for Cancer Research (CCR), RNA Biology Laboratory have developed an assay for detecting transcription errors and mutagenicity in RNA synthesis. This new assay would be an alternative to the standard Ames test, which is FDA-recommended for drug approval as it assesses the in vivo mutagenic and carcinogenic potential of a drug.
Researchers at the National Cancer Institute (NCI) have developed an engineered storage unit for frozen tissue, that provides a permanent base on which to mount tissue frozen in OCT and an enclosure for storage. The unit provides for chain-of-custody labeling and acts as an insulating container to protect the specimen. Other elements include devices for freezing the tissue to the base, as well as a holder for the base to facilitate cryosectioning. Application of the storage system allows a frozen tissue specimen to be moved between storage and cryosectioning without loss of label, deformation of tissue, or thermal alterations.